Key result
Higher baseline BNP levels (<100 pg/mL) were associated with 8-year increases in left atrial volume index, LV mass index, and E/e', with significantly stronger associations in type 2 diabetes.
Why the study?
Does higher baseline BNP in a non-heart failure range predict changes in markers of left ventricular function in individuals with and without type 2 diabetes?
Cohort (n=300)
Does higher baseline BNP in a non-heart failure range predict changes in markers of left ventricular function in individuals with and without type 2 diabetes?
Higher BNP levels within the normal, non-heart failure range predict future deterioration in left ventricular diastolic function and increased LV mass over 8 years, particularly in patients with type 2 diabetes.
May flag early LV remodeling risk in type 2 diabetes; leaves open whether BNP monitoring improves outcomes in non-HF patients.
OBJECTIVE: Heart failure is common in individuals with type 2 diabetes, and early detection of individuals at risk may offer opportunities for prevention. We aimed to explore 1) prospective associations of B-type natriuretic peptide (BNP) levels in a non-heart failure range with changes in markers of left ventricular (LV) function and 2) possible effect modification by type 2 diabetes in a population-based cohort. RESEARCH DESIGN AND METHODS: Echocardiographic measurements were performed at baseline (2000-2001) and follow-up (2007-2009), together with standardized physical examinations and BNP measurements on 300 individuals (mean age 66 years, 32% with type 2 diabetes) of the longitudinal Hoorn Study. Multivariate linear regression analyses were performed to investigate associations of baseline BNP (<100 pg/mL) in individuals without prevalent heart failure at baseline with changes in LV mass index, LV ejection fraction, left atrial volume index, and ratio of early diastolic LV inflow velocity (E) to early diastolic lengthening velocity (e') (E/e'). RESULTS: In all individuals, higher BNP was associated with 8-year increases in left atrial volume index. Higher BNP was also associated with increasing LV mass index and E/e'. These associations were significantly stronger in individuals with type 2 diabetes compared with the nonsignificant associations in individuals without type 2 diabetes. CONCLUSIONS: This 8-year follow-up study shows that higher BNP levels in a non-heart failure range were associated with an increased LV mass and deteriorated LV diastolic function, particularly in individuals with type 2 diabetes. This implies that the presence or absence of type 2 diabetes should be taken into account if BNP levels are used to assess future heart failure risk.
No takes yet. Share an insight, caveat, or question.
Kroon et al. (2012) conducted a cohort in Type 2 diabetes and heart failure risk (n=300). B-type natriuretic peptide (BNP) levels vs. Lower BNP levels was evaluated on Changes in LV mass index, LV ejection fraction, left atrial volume index, and E/e' ratio. Higher baseline BNP levels (<100 pg/mL) were associated with 8-year increases in left atrial volume index, LV mass index, and E/e', with significantly stronger associations in type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: